Loading stock data…
$9.89-0.63 (-5.99%)
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins.
Monte Rosa Therapeutics, Inc. in the Healthcare sector is trading at $9.89 with a market capitalization of $1.1B. Wall Street consensus targets $26.88 (8 analysts), implying a +171.7% move over the next 12 months. The stock is currently near its 52-week low of $8.94, remaining 45.0% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality. Risk note: RSI 24 is oversold, raising the odds of a near-term bounce. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $8.97M↑ | $4.21M↑ | $2.78M↓ | $12.77M↓ | $23.19M |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$49.13M↑ | -$50.03M↓ | -$49.72M↓ | -$32.98M↓ | -$15.55M |
| Net Income | -$43.40M↑ | -$44.50M↑ | -$46.13M↓ | -$27.08M↓ | -$12.29M |
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The comp...